PSTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Plus Therapeutics Inc (PSTV) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. The stock lacks immediate positive catalysts, has weak financial performance, and no significant trading signals. While analysts maintain a Buy rating, the price targets have been lowered due to dilution concerns, and the stock's technical indicators suggest a neutral trend. Therefore, it is better to hold off on investing in PSTV at this time.
The MACD is positive but contracting, indicating a lack of strong momentum. RSI is neutral at 52.127, and moving averages are converging, showing no clear trend. The stock is trading below its pivot level of 0.302, with support at 0.269 and resistance at 0.335. Overall, the technical indicators suggest a neutral trend.
Analysts see potential in the company's CNSide diagnostic and Reyobiq therapy, with a 'catalyst-rich' 2026 expected. The company has also received encouraging feedback from the FDA for its leptomeningeal metastases study.
Recent equity dilution has led to lowered price targets by analysts. Financial performance shows declining revenue (-4.05% YoY) and a significant drop in EPS (-89.19% YoY). There is no recent news or significant trading activity from insiders or hedge funds.
In Q3 2025, revenue dropped to $1,397,000 (-4.05% YoY), net income improved to -$4,423,000 (+53.90% YoY), EPS dropped to -0.04 (-89.19% YoY), and gross margin remained stable at 100%. Overall, the financials show weak revenue and profitability trends.
Analysts maintain a Buy rating but have lowered price targets due to dilution concerns. Lake Street has a $2 target, Maxim adjusted its target to $1.50 from $3, and H.C. Wainwright lowered its target to $1 from $2. Analysts see long-term potential but acknowledge near-term challenges.
